Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00378482
Status:
COMPLETED
Last Update Posted:
2023-11-14
First Post:
2006-09-19
Brief Title:
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Rollover Protocol For Patients Who Received Tremelimumab CP-675206 In Other Protocols
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-000989-23 | EUDRACT_NUMBER | AZ study code | None |
| D4881C00024 A3671024 | OTHER | None | None |